European equities traded in the US as American depositary receipts were trending modestly lower late Friday morning, down 0.23% to 1,399.64 on the S&P Europe Select ADR Index. Despite the decline, the ...
The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.
Banzai previously received a notification letter from the Nasdaq Listing Qualifications Department on August 6, 2024, notifying the Company that its market value of listed securities was below the ...
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They ...
CARDIFF, UK / ACCESS Newswire / February 12, 2025 / Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage biopharmaceutical company developing a pipeline of innovative products for the treatmen ...
Biodexa Pharmaceuticals (BDRX) received Fast Track status from the U.S. Food and Drug Administration for eRapa, a proprietary encapsulated form ...
CARDIFF, UK / ACCESS Newswire / February 12, 2025 /Biodexa Pharmaceuticals PLC. (NASDAQ:BDRX), a clinical-stage ...